Evidence map›Paper›PMID 33147871›Full record

ArticleMicroorganisms2020

New Insights in Laboratory Testing for COVID-19 Patients: Looking for the Role and Predictive Value of

Annalisa Schirinzi, Angela Pia Cazzolla, Roberto Lovero, Lorenzo Lo Muzio, Nunzio Francesco Testa, Domenico Ciavarella, Giuseppe Palmieri, Pietro Pozzessere, Vito Procacci, Francesca Di Serio and 1 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Microorganisms, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04840940 (Presepsin as an Early Biomarker for Ventilator-associated Pneumonia), which is not on this map. Cited by 29 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 2 pooled it
0.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04840940 unknown statusnot on this map

Presepsin as an Early Biomarker for Ventilator-associated Pneumonia (VAP) Diagnosis in COVID-19 Patients: a Prospective Double Blind Observational Study

TypeobservationalSponsorSan Luigi Gonzaga HospitalRan2020 to 2021Enrolled50ConditionsVentilator Associated Pneumonia, Covid19
3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 2 syntheses or guidelines pooled it, 44 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Current Views About the Link between SARS-CoV-2 and the Liver: Friends or Foe?Endocrine, metabolic & immune disorders drug targets · 2024
    Article
  11. Article
  12. Oral microbiota in human health and disease: A perspective.Experimental biology and medicine (Maywood, N.J.) · 2023
    Review
  13. Article
  14. Ovarian Cancer Biomarkers in the COVID-19 Era.International journal of environmental research and public health · 2023
    Article
  15. Observational
  16. Review
  17. Update on COVID-19 and Effectiveness of a Vaccination Campaign in a Global Context.International journal of environmental research and public health · 2022
    Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Annalisa SchirinziAOU Policlinico Consorziale di Bari-Ospedale Giovanni XXIII, Clinical Pathology Unit, 70124 Bari, Italy.
Angela Pia CazzollaDepartment of Clinical and Experimental Medicine, Università degli Studi di Foggia, 71122 Foggia, Italy.
Roberto LoveroAOU Policlinico Consorziale di Bari-Ospedale Giovanni XXIII, Clinical Pathology Unit, 70124 Bari, Italy.
Lorenzo Lo MuzioDepartment of Clinical and Experimental Medicine, Università degli Studi di Foggia, 71122 Foggia, Italy.ORCID 0000-0003-4633-4893
Nunzio Francesco TestaDepartment of Clinical and Experimental Medicine, Università degli Studi di Foggia, 71122 Foggia, Italy.
Domenico CiavarellaDepartment of Clinical and Experimental Medicine, Università degli Studi di Foggia, 71122 Foggia, Italy.
Giuseppe PalmieriPrivate Practice, 70124 Bari, Italy.
Pietro PozzessereAOU Policlinico Consorziale di Bari-Ospedale Giovanni XXIII, Emergency Medicine and Surgery Unit, 70124 Bari, Italy.
Vito ProcacciAOU Policlinico Consorziale di Bari-Ospedale Giovanni XXIII, Emergency Medicine and Surgery Unit, 70124 Bari, Italy.
Francesca Di SerioAOU Policlinico Consorziale di Bari-Ospedale Giovanni XXIII, Clinical Pathology Unit, 70124 Bari, Italy.
Luigi SantacroceIonian Department (DJSGEM), Microbiology and Virology Lab, Università Degli Studi di Bari, 70124 Bari, Italy.ORCID 0000-0001-5671-8124
Ospedale Pediatrico Giovanni XXIII · ITUniversity of Foggia · ITUniversity of Bari Aldo Moro · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

COVID-19 is a viral pandemic caused by the new coronavirus SARS-CoV-2, an enveloped positive stranded RNA virus. The mechanisms of innate immunity, considered as the first line of antiviral defense, is essential towards viruses. A significant role in host defense of the lung, nasal and oral cavities is played by Human epididymis secretory protein 4 (HE4) HE4 has been demonstrated to be serum inflammatory biomarker and to show a role in natural immunity at the level of oral cavity, nasopharynx and respiratory tract with both antimicrobial/antiviral and anti-inflammatory activity. Several biomarkers like IL-6, presepsin (PSP), procalcitonin (PCT), CRP, D-Dimer have showed a good function as predictor factors for the clinical evolution of COVID-19 patients (mild, severe and critical). The aim of this study was to correlate the blood levels of CRP, IL-6, PSP, PCT, D-Dimer with He4, to identify the predictive values of these biomarkers for the evolution of the disease and to evaluate the possible role of HE4 in the defense mechanisms of innate immunity at the level of oral cavity, nasopharynx and respiratory tract. Of 134 patients admitted at COVID hospital of Policlinico-University of Bari, 86 (58 men age 67.6 ± 12.4 and 28 women age 65.7 ± 15.4) fulfilled the inclusion criteria: in particular, 80 patients (93%) showed prodromal symptoms (smell and/or taste dysfunctions) and other typical clinical manifestations and 19 died (13 men age 73.4 ± 7.7 and 6 women age 74.8 ± 6.7). 48 patients were excluded because 13 finished chemotherapy and 6 radiotherapy recently, 5 presented suspected breast carcinoma, 5 suspected lung carcinoma, 6 suspected ovarian carcinoma or ovary cyst, 1 cystic fibrosis, 3 renal fibrosis and 9 were affected by autoimmune diseases in treatment with monoclonal antibodies. The venous sample was taken for each patient on the admission and during the hospital stay. For each patient, six measurements relating to considered parameters were performed. Significant correlations between He4 and IL-6 levels (

Indexed as

COVID-19Human epididymis secretory protein 4 (HE4)innate immunityinterleukin-6 (IL-6)laboratory testpresepsin (PSP)procalcitonin (PCT)SARS-CoV-2

Identifiers

PMID33147871
PMCPMC7692217
OpenAlexW3096865789

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.